AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04031599 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Carbohydrate counting
Description: Participants will be required to enter an estimate of the carbohydrate content of their meal into the phone. Insulin boluses will be calculated based on grams of carbohydrates and participant's insulin-to-carbohydrate ratio. Carbohydrate-matching full prandial bolus will be given 5 to 10 minutes before the meal.
Study NCT04031599 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Simplified qualitative meal-size estimation strategy
Description: A pre-meal partial prandial bolus will be given 5-10 minutes before the meal. The partial bolus will be based on the estimated meal size (small, regular, large and extra-large). The closed-loop system will give the remaining insulin needed based on the sensor readings. For this strategy, meal size will be defined as: small as any meal less than 30g, regular meal as any meal between 30g and 60g CHO, large meal as any meal between 60g and 90g CHO, extra-large meal for anything above 90g CHO.
Study NCT04031599 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 3-week intervention
Description: Glucose levels will be regulated by the single-hormone closed-loop system for 3 consecutive weeks.
Study NCT04031599 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 1-hour postprandial exercise (sub-study)
Description: 60 minute exercise will be started one hour after the meal time.
Study NCT04031599 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 2-hour postprandial exercise (sub-study)
Description: 60 minute exercise will be started two hours after meal time
Study NCT04031599 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise announcement and meal bolus reduction (sub-study)
Description: Meal bolus reduction of 33% at meal time and exercise announcement (increased target glucose from 6 to 9mmolL) to the CLS algorithm
Study NCT01378364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AbGn-168H
Description: single very low dose of AbGn-168H i.v.
Study NCT01378364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AbGn-168H
Description: single low dose of AbGn-168H i.v.
Study NCT01378364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: single dose of Placebo i.v.
Study NCT01378364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AbGn-168H
Description: single medium dose of AbGn-168H i.v.
Study NCT01378364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AbGn-168H
Description: single high dose of AbGn-168H i.v.
Study NCT01378364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AbGn-168H
Description: single low dose of AbGn-168H s.c.
Study NCT01378364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: single dose of Placebo s.c.
Study NCT01378364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AbGn-168H
Description: single medium dose of AbGn-168H s.c.
Study NCT01740830 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Direct Current Stimulation (tDCS) (Neuroconn DC-stimulator)
Description: The anode will be fixed over the primary motor cortex. The cathode will be fixed over the contralateral supraorbital region.
Study NCT01740830 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Direct Current Stimulation (tDCS) (Neuroconn DC-stimulator)
Description: The anode will be fixed over the primary motor cortex. The cathode will be fixed over the contralateral supraorbital region.
Study NCT01392144 — intervention group
Intervention type: PROCEDURE
Intervention: Nitric oxide breath test
Description: Breathe out into a device (nitric oxide breath analyzer) for 10 seconds; repeated 3 times. Done prior to start of radiation therapy, 1 week before completion of radiation therapy, at completion of radiation therapy, then at each follow-up visit for 6 months.
Study NCT01392144 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: On day of each breathing test, completion of a breathing and symptom questionnaire, approximately 10 minutes.
Study NCT02432703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42165279
Description: Participants will receive 25 milligram (mg) JNJ-42165279 orally once-daily from Day 1 up to 12 weeks.
Study NCT02432703 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive a matching placebo orally once-daily from Day 1 up to 12 weeks.
Study NCT03730909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Lactate
Description: IV infusion
Study NCT03730909 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium chloride
Description: IV infusion
Study NCT04609098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin/Piperaquine
Description: Tablets containing 40 mg dihydroartemisinin/320 mg piperaquine (Eurartesim, Sigma Tau), administered according to weight as per the manufacturer instructions.
Study NCT04609098 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dihydroartemisinin/Piperaquine
Description: Tablets containing 40 mg dihydroartemisinin/320 mg piperaquine (Eurartesim, Sigma Tau), administered according to weight as per the manufacturer instructions.
Study NCT04609098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafenoquine 100mg [Arakoda]
Description: Extemporaneous preparation of 1mg/mL Tafenoquine solution, from tablets containing 100mg primaquine (Arakoda, 60degrees pharmaceuticals, DC) dissolved in 100mL water with a non-interacting fruit-flavoured syrup. Solution will be given according to weight as indicated per treatment arm in 5kg bands.
Study NCT02267239 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: essential oils, immersion
Description: A single, 30-second immersion in 1 mL of essential oils in a hydroalcoholic solution (Listerine Mentol, Listerine®, Johnson \& Johnson, Madrid, Spain) (I-EO).
Study NCT02267239 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine, immersion
Description: A single, 30-second immersion in 1 mL of 0.2% chlorhexidine (Oraldine Perio®, Johnson and Johnson, Madrid, Spain) (I-0.2% CHX).
Study NCT02267239 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: essential oils, mouthwash
Description: A single, 30-second mouthwash with 20 mL of essential oils in a hydroalcoholic solution (Listerine Mentol, Listerine®, Johnson \& Johnson, Madrid, Spain) (M-EO).
Study NCT02267239 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chlorhexidine, mouthwash
Description: A single, 30-second mouthwash with 10 mL of 0.2% chlorhexidine (Oraldine Perio®, Johnson and Johnson, Madrid, Spain) (M-0.2% CHX).
Study NCT02267239 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: professional oral cleaning
Description: scaling and polishing teeth of the volunteers
Study NCT02267239 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: professional oral cleaning
Description: scaling and polishing teeth of the volunteers
Study NCT02267239 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Plaster cast
Description: Taking a plaster cast of the volunteers' mouth
Study NCT02267239 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Plaster cast
Description: Taking a plaster cast of the volunteers' mouth
Study NCT02267239 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IDODS
Description: Specific intraoral device which carries six glass disks
Study NCT02267239 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: IDODS
Description: Specific intraoral device which carries six glass disks
Study NCT02412306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Continuous intravenous infusion over four weeks per treatment cycle
Study NCT02327546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AKB-6548
Study NCT02327546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferrous Sulfate
Study NCT03507842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose Cytarabine
Description: High dose Cytarabine 3.0 g/m2 q12hr 3-hour iv infusion on days 1, 3, 5 plus daunorubicin 45 mg/m2/day continuous iv infusion for 3 days (D1-3).
Study NCT03507842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: cytarabine 200 mg/m2/day continuous iv infusion for 7 days (D1-7)
Study NCT03507842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hign dose Daunorubicin
Description: Hign dose Daunorubicin 90 mg/m2/day continuous iv infusion for 3 days (D1-3).
Study NCT01126749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine
Study NCT01126749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7389
Description: E7389
Study NCT01126749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin
Study NCT00976274 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Korean red ginseng
Description: 5 capsules (300 mg/capsule) three times everyday for 12 weeks
Study NCT00976274 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: starch
Description: 5 capsules three times everyday for 12 weeks
Study NCT02642601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indomethacin(KAHIRA PHARMA&CHEM,IND,CO.CAIRO-EGYPT)
Description: one dose of indomethacin 100 mg rectal suppository 1- 2 hours before embryo transfer
Study NCT02183675 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan/Amlodipine
Description: Telmisartan/Amlodipine fixed-dose combination
Study NCT02183675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan/Amlodipine/HCTZ
Description: Telmisartan/Amlodipine/HCTZ fixed-dose combination
Study NCT02183675 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan/HCTZ
Description: Telmisartan/HCTZ fixed-dose combination
Study NCT03337308 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Bempedoic Acid + Ezetimibe Fixed-Dose Combination
Description: bempedoic acid + ezetimibe FDC 180 mg/10 mg tablet
Study NCT03337308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bempedoic Acid
Description: bempedoic acid 180 mg tablet
Study NCT03337308 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ezetimibe
Description: ezetimibe 10 mg overencapsulated tablet
Study NCT03337308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos
Description: placebo tablet or capsule to match bempedoic acid + ezetimibe fixed-dose combination (FDC) 180 mg/10 mg tablet, or bempedoic acid 180 mg tablet, or ezetimibe 10 mg capsule
Study NCT03337308 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebos
Description: placebo tablet or capsule to match bempedoic acid + ezetimibe fixed-dose combination (FDC) 180 mg/10 mg tablet, or bempedoic acid 180 mg tablet, or ezetimibe 10 mg capsule
Study NCT03337308 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: placebo tablet or capsule to match bempedoic acid + ezetimibe fixed-dose combination (FDC) 180 mg/10 mg tablet, or bempedoic acid 180 mg tablet, or ezetimibe 10 mg capsule
Study NCT01926223 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home visiting
Study NCT02558725 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: two capsules of aktiferrin F
Description: two capsules of Aktiferrin F or Foliferrin
Study NCT03305614 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS
Description: C-tDCS during the first 20 minutes of aphasia therapy, at an intensity of 1mA or sham-tDCS at an intensity of 0mA
Study NCT03305614 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Aphasia therapy
Description: Based on linguistic tests, individualized aphasia therapy will be provided
Study NCT03305614 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Aphasia therapy
Description: Based on linguistic tests, individualized aphasia therapy will be provided
Study NCT03559114 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dalteparin
Description: Dalteparin in prophylactic doses administered daily if screening criteria are satisfied.
Study NCT03559114 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline in prophylactic doses administered daily if screening criteria are satisfied.
Study NCT04738227 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low-Level Laser Therapy
Description: Low level laser will be applied and post laser results will be seen to assess any improvements.
Study NCT04326595 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgical and medical evacuation
Description: surgical evacuation:the dilation of the cervix and surgical evacuation of the uterus (potentially including the fetus, placenta and other tissue) medical evacuation: induction of abortion by the use of ecbolics
Study NCT00569556 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Case Management
Description: Phone contact by specially trained nurse case managers; lifestyle recommendations and medication changes as needed
Study NCT00569556 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Case Management
Description: Phone contact by specially trained nurse case managers; lifestyle recommendations and medication changes as needed
Study NCT02139761 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: l-tetrahydropalmatine (l-THP)
Description: Subjects will be dosed 30 mg BID (2 capsules total a day, total of 60mg/day), matching placebo or l-THP) (total 60 mg daily). The half-life of l-THP is about 10 hours, so subjects will reach steady state in about 2-3 days. The l-THP will be prepared at the University of Maryland School of Pharmacy to Chemistry under Good Manufacturing Practice (GMP) and standards. The identical placebo and active capsules will be manufactured and sent to the Maryland Psychiatric Research Center Pharmacy, where they will be stored, randomized and dispensed. Medication will be transported by the study staff to the participant once dispensing occurs.
Study NCT02139761 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will be dosed 30 mg BID (2 capsules total a day, total of 60mg/day), matching placebo or l-THP) (total 60 mg daily). The half-life of l-THP is about 10 hours, so subjects will reach steady state in about 2-3 days. The l-THP will be prepared at the University of Maryland School of Pharmacy to Chemistry under Good Manufacturing Practice (GMP) and standards. The identical placebo and active capsules will be manufactured and sent to the Maryland Psychiatric Research Center Pharmacy, where they will be stored, randomized and dispensed. Medication will be transported by the study staff to the participant once dispensing occurs.
Study NCT01794429 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exenatide
Description: Subcutaneum injection of exenatide once-weekly for 3 months
Study NCT01794429 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneum injection of placebo once-weekly for 3 months
Study NCT01241864 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogenic islet cells (human, U. Chicago)
Description: Human allogenic islet cells. Immunosuppression varies but may include prograf, cellcept, sirolimus, prednisone. Dosage will vary per patient based on weight. Patients will receive immunosuppression medications while islet cells are functioning.
Study NCT01241864 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraportal infusion of islet cells
Description: Intraportal infusion of islet cell through the portal vein in the liver.
Study NCT04703738 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Soft tissue flap + Connective Tissue Graft
Description: The treatment site is accessed using a full thickness flap extending at least 1 full tooth mesial and distal, vertical releasing incisions may be used to obtain flap release for full coverage of the treatment site and graft without compression. The harvest graft donor area will be the palate in the bicuspid region on the same side as the control soft tissue augmentation therapy. The CTG will be harvested using full thickness incisions that include the periosteum and will be closed using suture and coating the incision line with a tissue adhesive. No covering stents or packs should be employed. The CTG will be sling sutured in place and the flap secured using a double sling suturing technique.
Study NCT04703738 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Soft tissue flap + Geistlich Fibro-Gide®
Description: The treatment site is accessed using a full thickness flap extending at least 1 full tooth mesial and distal, vertical releasing incisions may be used to obtain flap release for full coverage of the treatment site and matrix without compression. Geistlich Fibro-Gide® is cut to shape to the treatment site and placed dry into the site. The flap is secured using a double sling suturing technique.
Study NCT03996343 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endotracheal intubation
Description: COMPLETE
Study NCT03996343 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway
Description: COMPLETE
Study NCT00267085 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Synthetic Tumor-Specific Breakpoint Peptide Vaccine
Description: CML vaccine, Imatinib mesylate, subcutaneously every 2 weeks x 4 weeks, then every three weeks x 1 week, then monthly for 10 months
Study NCT01721460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine infusion will be started with a loading dose of 1 mcg/Kg over ten to 20 minutes followed by a maintenance infusion of 0.7 mcg/Kg/hr until stable sedation is achieved.
Study NCT03173924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-NaF
Description: Baseline IV followed by PET/CT IMAGING
Study NCT03173924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-DCFPyL
Description: Baseline IV followed by PET/CT IMAGING. Additional 18F-DCFPyL PET/CTs might be performed during the subject s follow up period if, in the opinion of the referring clinician, there has been a considerable change in patient status (progression or response) based on clinical grounds/PSA value or to help assess changes of standard of care therapy.
Study NCT03173924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-FDG
Description: Baseline IV followed by PET/CT IMAGING. Additional 18F-FDG PET/CTs may be obtained per PI discretion within a 21-day window relative to each 18F-DCFPyL PET/CTs.
Study NCT02712346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ambrisentan
Description: Ambrisentan 5 milligrams a day or a placebo (sugar pill) for twelve weeks
Study NCT02712346 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One inactive pill daily for twelve weeks
Study NCT02362815 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Apple juice
Description: Intervention consists in allowing drinks during labour
Study NCT02769923 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Westpharma ID adapter
Description: device used for administering intradermal injection
Study NCT02769923 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Star ID syringe
Description: device used for administering intradermal injection
Study NCT02769923 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BCG NS
Description: syringe used for administering intradermal injection
Study NCT01131975 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamotrigine
Description: Lamotrigine Tablets (chewable, dispersible), 25 mg
Study NCT01131975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Description: Lamotrigine Tablets (chewable, dispersible), 25 mg
Study NCT00374140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001 (everolimus)
Description: 10 mg by mouth daily without interruption for 3-week cycles until disease progression or intolerable toxicities
Study NCT03999996 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Takeda's Dengue Tetravalent Vaccine (Live, Attenuated) (TDV)
Description: TDV subcutaneous injection
Study NCT03220971 — intervention group
Intervention type: OTHER
Intervention: lipoprotein and apolipoproteins
Description: To find out the role of lipoprotein and apolipoproteins (apos) in pathogenic hepatic diseases
Study NCT03999996 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal Saline (0.9% NaCl) subcutaneous injection
Study NCT02847247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CCRE
Description: Endotoxin challenge: Subjects will undergo inhalation of 20,000 EU CCRE. The CCRE will be inhaled by subjects as a nebulized preparation using an ultrasonic nebulizer until the challenge solution is completely spent (generally 10 minutes).
Study NCT04694443 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Multidisciplinary tele-health intervention (physical therapy, neurologist, nurse, psychologist)
Description: Non-pharmacological and pharmacological treatment provided by telemedicine plus in-office visits